Less speed means less metabolic stress
(2017) "Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial" The Lancet Diabetes & Endocrinology, 5(4) This article was reviewed by and approved by Alice Fletcher, Lead Bariatric Dietitian, on 3 April 2025
Jun 07, 2026, 17:30 ET CagriSema, a once-weekly investigational treatment that combines a novel amylin analog with a GLP-1 receptor agonist (RA), achieved significant reductions in HbA 1c and bodyweight versus comparators across three phase 3 trials in adults with type 2 diabetes (T2D) 1-3 Data from the REIMAGINE clinical development program, a series of phase 3 trials evaluating once-weekly CagriSema in adults with T2D across various stages of their disease, were presented at an ADA symposium 1-3 Novo Nordisk continues to demonstrate pioneering leadership and scientific innovation through advancing diabetes research PLAINSBORO, N.J
Her doctor then recommended a GLP-1 drug, but getting insurance coverage was a challenge, requiring an extensive pre-authorization process and two appeals
5.7 Severe Gastrointestinal Adverse Reactions Use of OZEMPIC has been associated with gastrointestinal adverse reactions, sometimes severe [see Adverse Reactions (6)]
